THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY

被引：0
|
作者：
Tam, C. [1 ]
Roberts, A. [2 ]
Anderson, M. A. [2 ]
Dawson, S. J. [1 ]
Hicks, R. [1 ]
Pott, C. [3 ]
Westerman, D. [1 ]
Burke, G. [1 ]
Kamel, S. [4 ]
Dreyling, M. [5 ]
Dawson, M. [1 ]
Seymour, J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
[2] Melbourne Hlth, Parkville, Vic, Australia
[3] Univ Hosp Schleswig Holstein, Kiel, Germany
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Munich, Munich, Germany
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P316
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
    Tam, Constantine Si Lun
    Roberts, Andrew Warwick
    Anderson, Mary Ann
    Dawson, Sarah-Jane
    Hicks, Rodney J.
    Pott, Christiane
    Westerman, David A.
    Burke, Glenda
    Kamel, Sarah
    Dreyling, Martin H.
    Dawson, Mark A.
    Seymour, John Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
    Handunnetti, Sasanka M.
    Anderson, Mary Ann
    Burbury, Kate
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Agarwal, Rishu
    Dawson, Mark A.
    Dawson, Sarah-Jane
    Koldej, Rachel
    Ritchie, David
    Seymour, John F.
    Roberts, Andrew W.
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [3] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [4] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [5] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [6] A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
    Gerecitano, John F.
    Roberts, Andrew W.
    Seymour, John F.
    Wierda, William G.
    Kahl, Brad S.
    Pagel, John M.
    Puvvada, Soham
    Kipps, Thomas J.
    Anderson, Mary Ann
    Dunbar, Martin
    Zhu, Ming
    Gressick, Lori
    Wagner, Lindsay
    Kim, Su Young
    Enschende, Sari Heitner
    Humerickhouse, Rod A.
    Davids, Matthew S.
    BLOOD, 2015, 126 (23)
  • [7] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [8] A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma
    Lee, Hun J.
    Schmelz, Jacob L.
    Cramer, Fred
    Romaguera, Jorge E.
    Badillo, Maria
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : E94 - E98
  • [9] Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results
    Kumar, Shaji K.
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph R.
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Moreau, Philippe
    Amiot, Martine
    Alzate, Stefanie
    Morris, Lura
    Ross, Jeremy
    Dunbar, Martin
    Zhu, Ming
    Maciag, Paulo
    Agarwal, Suresh
    Leverson, Joel
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Touzeau, Cyrille
    BLOOD, 2015, 126 (23)
  • [10] Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
    Jones, Jeffrey
    Mato, Anthony R.
    Coutre, Steven
    Wierda, William
    Choi, Michael Y.
    Davids, Matthew S.
    Lamanna, Nicole
    Barr, Paul
    Burns, Kim
    Montalvo, Nicholas
    Zhu, Ming
    Busman, Todd
    Potluri, Jalaja
    Humerickhouse, Rod A.
    Byrd, John C.
    BLOOD, 2015, 126 (23)
12345